We initiate coverage on Intuitive Surgical with a Hold rating and a $420.00 price target. At 29.1 times 2027 estimated non-GAAP earnings, the stock fairly balances 14% procedure growth and a clean balance sheet against moderating system replacement demand.
Key points
- $407.99 prices Intuitive Surgical at 29.1 times 2027 estimated non-GAAP earnings per share of $14.00, fairly reflecting mid-teens procedure expansion.
- 75% of revenue is recurring instruments, accessories, and contracted services, insulating cash flow from tightening hospital equipment budgets.
- $450 million antitrust class action settlement resolves a long-standing legal overhang without disrupting the core da Vinci instrument ecosystem.
The call
The current stock price implies Intuitive can sustain 18% annual top-line growth and expand operating margins toward 42% over the next two years. That expectation assumes da Vinci 5 placements translate immediately into procedure re-acceleration, while hospital capital spending remains completely resilient against macroeconomic pressures.
Quarterly revenue progression ($ billions)- Reported quarterly revenue ($B)
- Forecast quarterly revenue ($B)
Reported Q3 2024 to Q3 2026 from SEC filings; Q4 2026E to Q4 2027E firm forecasts.
We believe worldwide da Vinci procedure growth will settle near 14% in 2027 rather than re-accelerating. Trade-in demand drives current placements rather than greenfield hospital expansion, while GLP-1 weight-loss medications continue to depress bariatric volumes. At 29 times earnings, the stock fairly reflects Intuitive's elite moat, producing balanced risk and reward.
Q3 2026 revenue breakdown: 75% recurring stream- Instruments & Accessories59%
- Systems25.2%
- Services15.8%
Third-quarter 2026 revenue components from SEC Form 8-K furnished October 20, 2026.
Valuation
| Valuation driver | 2027 estimate |
|---|
| Worldwide da Vinci procedure growth | 14.0% |
| Total revenue ($ billions) | $13.78 |
| Non-GAAP operating margin | 41.1% |
| Non-GAAP diluted EPS | $14.00 |
| Target P/E multiple | 30.0× |
| 12-month price target | $420.00 |
A 30 times multiple aligns with large-cap medical technology leaders growing earnings at mid-teens rates with debt-free balance sheets. Holding $6.80 billion in cash and investments protects against capital expenditure cycles. The 3% upside to our $420.00 price target indicates the stock will track the broader market over the coming year.
Risks
- Hospital budget cuts: Capital placement deferrals and leasing shifts would lower near-term system revenue; watch quarterly da Vinci operating lease conversion rates.
- GLP-1 procedure displacement: Continued uptake of anti-obesity drugs could spill from bariatric surgeries into general laparoscopic procedures; watch U.S. general surgery volume trends.
- Antitrust settlement injunctive terms: Restrictive court requirements on instrument servicing could pressure replacement frequency; watch the final court approval filing.
What would change my mind
A re-acceleration in organic da Vinci procedure growth above 17% alongside rapid international da Vinci 5 adoption would warrant an upgrade to Buy.